The review concluded that blood pressure response to calcium channel blocker monotherapy was qualitatively similar in blacks and whites in USA. The authors' conclusions appeared to broadly reflect the evidence presented, but the restriction of using only trial data and limitations in the review processes made their reliability uncertain.
and whites was -2.7mmHg (95% CI -4.0 to -1.3; four cohorts) and for diastolic blood pressure was -0.4mmHg (95% CI -1.0 to 0.3; six cohorts) with blacks having greater response. There was no indication of publication bias for the diastolic analysis, but there was for the systolic analysis.
However, whites were just as likely as blacks to attain a diastolic blood pressure goal of less than 90mmHg or a 10mmHg or greater change (RR 1.00, 95% CI 0.91 to 1.11), with little evidence of publication bias.
Authors' conclusions
Blood pressure response was qualitatively similar in blacks and whites in USA, which suggested that patient race was unlikely to offer any clinical utility for decisions about the likely effect of calcium channel blocker monotherapy.
CRD commentary
The review addressed a clear question and was supported by appropriate inclusion criteria (although exact details of eligible study designs were not specified). Attempts to identify relevant studies were undertaken by searching electronic databases and the restriction to including studies in USA meant that language bias would be unlikely to be an issue. The authors did not search for unpublished studies, so some relevant data may have been missed. Suitable methods were not employed to reduce risks of reviewer error and bias during data extraction. The authors did not report on whether methods such as independent duplicate assessment were used to select studies for inclusion.
Very little detail was presented about study design and no formal study quality assessment was made. The analyses were of active treatment-arm trial data, so it was unclear (considering the authors' objective) why studies without control arms were not included to maximise the evidence available. Appropriate methods were used to pool data and heterogeneity was assessed, with possible causes investigated and discussed. The authors noted that none of the trials reported socioeconomic, psychological or behavioural data, so investigation of these covariates was not possible.
The authors' conclusions appeared to broadly reflect the evidence presented, but the restriction of using only trial data and limitations in the review processes made their reliability uncertain.
Implications of the review for practice and research
Practice: The authors stated that the absence of quantitative evidence for substantial differences in blood pressure response ruled out a rational role for patients' race in clinical decisions about the use of calcium channel blocker monotherapy.
